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Context:About 10%of pheochromocytomas aremalignant. Exact survival has not been reported,
nor has an analysis of the efficacy of chemotherapy on survival time.
Objective:Theaimof this studywas toanalyze thesurvival curvesandsurvival timesofpatientswith
malignant pheochromocytoma and to determine the efficacy of chemotherapy on prolongation
of life.
Design: An inception cohort and Kaplan-Meier survival analysis was conducted.
Patients and OutcomeMeasured: Thirty-two patients with metastasized malignant pheochromo-
cytoma were analyzed for survival. Twenty-five patients had undergone excision of their primary
tumors. Survival curveswere comparedamong the16patients in this group treatedwith combined
chemotherapy using cyclophosphamide, vincristine and dacarbazine (CVD) and the nine patients
not treated with chemotherapy.
Results:Thesurvival curveof the32patientsdeclinedcontinuouslyand linearly toat least20yrafter
the diagnosis of pheochromocytoma. The 50% survival rate was estimated to be 14.7 yr. In the 25
patients whose primary tumor was excised, patients who already had metastases at the time of
pheochromocytoma diagnosis had better survival than those whose metastases were found later.
The survival rate after diagnosis of metastasis was worse in the CVD group than in controls. When
the effects of CVD were examined after stratifying several factors, female gender and adrenal
origin of tumor were found to be negative prognostic factors for CVD chemotherapy.
Conclusion: The present study revealed a long survival time. CVD chemotherapywas not shown to
extend survival, especially for women and patients with adrenal gland-derived primary tumors.
(J Clin Endocrinol Metab 94: 2850–2856, 2009)
Pheochromocytomas produce and secrete catecholamines.They mostly occur in the adrenal medulla, but may also
present in the extraadrenal sympathetic nervous system as para-
ganglioma.About10%ofpheochromocytomasaremalignant in
nature. However, even pathological examination of surgically
excised tumors cannot be used to discriminatemalignant tumors
from benign ones. The gold standard for diagnosing malignant
pheochromocytoma, atpresent, is evidenceof ametastatic tumor
in the non-chromaffin tissues. The period from disease onset to
recurrence is highly variable (1, 2). Somemetastatic tumors may
become prominent after more than 20 yr. This tumor’s variable
growth rate and rare incidence have made it difficult for studies
to determine the exact prognosis of patients and therefore to
determine the efficacy of the present therapeutic strategy. Sur-
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vival rates that have been reported previously were based on a
small number of patients andwere so fragmented anddescriptive
that they could not reveal a pattern in the survival curve, i.e.
continuous or intermittent; or linear, convex, or concave. We
have used an inception cohort studywith a significant number of
patients with malignant pheochromocytomas using Kaplan-
Meier survival analysis to reveal the survival curves and times for
these patients.
The main therapeutic strategy for this tumor is surgical ex-
cision or debulking of accessible tumors (3). Internal radiation
using 131I-metaiodobenzylguanidine (131I-MIBG) (4) and/or
chemotherapy has also been used. Combination chemotherapy
using cyclophosphamide, vincristine, and dacarbazine (CVD)
may be the most popular regimen for malignant pheochromo-
cytoma. Its antineoplastic effect has been recently reviewed as
being limited, and relapse occurred within 2 yr in most patients
(5).Reports on the efficacy ofCVDchemotherapywere basedon
results using surrogate endpoints such as changes in tumor vol-
ume or hormone levels. The effect on survival time remains to be
determined. A randomized controlled trial with an endpoint of
mortality or survival rate is generally considered to be the most
valid to clarify the efficacy of treatment but is difficult in practice
in the case of malignant pheochromocytoma. As the next best
thing, patients with or without chemotherapy can be compared
in their survival times after conditioning their profiles.
The present study sought to determine the survival curves in
patients with malignant pheochromocytoma and to evaluate
whether CVD chemotherapy could extend patients’ lives.
Patients and Methods
Diagnosis and evaluation of disease
Patients were diagnosed as having pheochromocytoma or paragan-
glioma based on a hormonal evaluation and imaging studies including
computed tomography, magnetic resonance imaging, and 131I-MIBG
scans. The timewhen these results were obtainedwas defined as the time
of pheochromocytoma diagnosis. Patientswere diagnosed as havingma-
lignant tumors ifmetastaseswere present in nonchromaffin sites orwhen
invasion of neighboring tissue was seen. Sites of metastases were classi-
fied as follows: pulmonary, bone, liver, or local. Local metastases in-
cluded invasion into neighboring tissues, recurrence at the site where the
primary tumor had been excised, and dissemination into the abdominal
cavity and regional lymph nodes. The time of the discovery of metastasis
or invasion was defined as the time of metastasis diagnosis. As described
below, pheochromocytoma and metastasis were diagnosed at the same
time in 14 patients. Urinary excretion of metanephrines (metanephrine
and normetanephrine) was measured as described previously (6).
Inclusion and exclusion criteria for patients
Thirty-two patients were diagnosed and treated as suffering from
malignant pheochromocytomas in our hospital between 1985 and 2006.
They were registered in a clinical database. Twenty-three patients were
referred to our hospital as metastatic pheochromocytoma patients.
Among these, 14 patients were already found to have metastases at the
time of diagnosis of pheochromocytoma. Nine patients were diagnosed
as havingmalignant pheochromocytoma after primary tumors had been
surgically removed previously in our hospital. Of the 32 patients in our
study, 18 had died and 14 were alive at the last follow-up on June 30,
2008. Their survival periodsweremeasured from twodifferent time zero
points: the time of pheochromocytoma diagnosis, and the time of me-
tastasis diagnosis.
In our study on the efficacy of chemotherapy, seven patients were
excluded; six had not been treated by surgical excision of the primary
tumor, and one had died due to intestinal bleeding after the primary
excision. Of the remaining 25 patients, 16 were treated with chemother-
apy using the CVD regimen (CVD group) and nine (control group) were
not. Twowomen in theCVDgroup stopped this therapy after one or two
rounds because of severe adverse effects including nausea, vomiting, and
generalmalaise. The otherCVDpatientswere treatedwithCVD therapy
at least four times. Survival time was compared between the control and
CVD groups by Kaplan-Meier survival analysis. The time zero for sur-
vivalwas the timeof diagnosis ofmetastasis because this also represented
the time of diagnosis ofmalignant pheochromocytoma andwas the clos-
est event to the initiation of CVD chemotherapy.
Therapy with or without CVD
CVD chemotherapy was administered according to the original
method of Keiser et al. (7): a combination of cyclophosphamide, 750
mg/m2 body surface on d 1; vincristine, 1.4 mg/m2 body surface on d 1;
and dacarbazine, 600 mg/m2 body surface on d 1 and 2, with this pro-
tocol repeated every 21–28 d.
131I-MIBG radiotherapy (8, 9), transcatheter arterial embolization
(TAE), and surgical debulking of metastasized tumors were also per-
formed in some patients (Table 1).
All of these therapies except 131I-MIBG radiotherapy are physically
taxing on patients. Therefore, according to the principles of our insti-
tution, they were given only to patients with a relatively stable condition
andwere not given to patients whowere estimated to be too ill to benefit
from a new and aggressive therapy. There were no standard criteria for
the selection of therapies for different patients. The risk and benefit of
therapies were dependent on patient’s condition and nature (site and
number)ofmetastatic tumor ingeneral and, therefore, differ casebycase.
We always evaluated patients carefully, along with surgeons and radi-
ologists with excellent skills, before the choice of therapy. Patients made
the final decision.
Statistics
Data are presented as means and SD values. An unpaired t test or
Fischer’s exact test was used to compare two groups. Survival was esti-
mated by the Kaplan-Meier method using Statistical Analysis System
software, ver. 9.1.3 (SAS Institute Inc., Cary, NC). Equality of each
group in Kaplan-Meier was estimated by the log-rank test.
Results
Survival analysis of 32 patients
Fourteen women and 18 men were included in the study.
Eighteen patients died, and 14 were alive at the last follow-up.
Twenty patients (62.5%) had paraganglioma. The primary tu-
mor was surgically excised in 26 patients. CVD chemotherapy
was given to 19 patients. Additional therapies were carried out
in some patients: six patients underwent an additional debulking
operation, four patients were treated with 131I-MIBG, and three
patients were treated with TAE.
A survival curve of 32 patients was analyzed from the time of
diagnosis of pheochromocytomabyKaplan-Meier survival anal-
ysis (Fig. 1A). The interval from time zero to the last follow-up
ranged from 0.5 to 39.7 yr (mean  SD, 10.7  9.4). The 75,
50, and 25% survival rates were estimated to be 5.5 yr [95%
confidence interval (CI), 2.3–12.2], 14.7 yr (95% CI, 8.2–
32.4), and 32.4 yr (95% CI, 18.5–39.7), respectively. Ex-
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pressed differently, the 5-, 10-, and 20-yr survival rates were
77.2, 61.3, and 39.5%, respectively. The survival rate de-
clined continuously and linearly.
The survival curve was also analyzed from the time of diag-
nosis of metastasis (the time of malignant pheochromocytoma
diagnosis) (Fig. 1B). The survival curve declined continuously
and linearly until 10 yr and then became flat until 23 yr, sug-
gesting that the curve was composed of two groups, i.e. patients
with short lives (n26) aftermetastasis and thosewith long lives
after metastasis (n  6; 18.8%). The 75, 50, and 25% survival
rateswere estimated to be 3.5 yr (95%CI, 1.4–5.8), 7.6 yr (95%
CI, 4.3–15.3), and 15.3 yr (upper range of 95%CI, 7.4), respec-
tively. The profiles of the six patients with long survival were
as follows: two were women and four were men, all had para-
ganglioma, all had excised primary tumors, three of these
patients showed metastasis at the time of pheochromocytoma
diagnosis, and three were treated with CVD (4, 8, and 20
times). Their average age at the time of metastasis diagnosis
was younger than that of the other 26 patients (37.0  13.8
vs. 52.3  13.1 yr; P  0.016).
We next examined the effects of gender, tumor type (adrenal
pheochromocytoma or extraadrenal paraganglioma), and time
of metastasis (presence or absence of metastasis at the time of
pheochromocytoma diagnosis) on a survival curve after the time
of metastasis diagnosis. Gender had no effect on the survival
curve (Fig. 2A). Tumor type also had no effect (2 1.412; P
0.2347 at log-rank test) (Fig. 2B). Patients withmetastases at the
time of pheochromocytoma diagnosis (termed early metastasis)
had a worse survival rate during the first 5 yr, but then had a
better survival rate than those without metastases at the time of
pheochromocytoma diagnosis (termed late metastasis). Overall,
the difference in survival time between patients with early or late
metastasis was statistically not significant (2  1.589; P 
0.2074) (Fig. 2C). Five patients who had not undergone surgical
excision of their primary tumors were included among the pa-
tients with early metastasis who died during the first 5 yr.
Comparison of profiles of 25 patients selected to
examine the effects of CVD chemotherapy
Wenext compared theprofiles of the control (n9) andCVD
(n  16) groups. Gender, age, tumor type (adrenal pheochro-
mocytoma or extraadrenal paraganglioma), treatments other
than CVD, mortality, sites of metastasis, and time from surgery
to metastasis were compared both at the time of pheochromo-
cytoma diagnosis and at the time of metastasis diagnosis (Table
1). No significant differences were observed in any of these fac-
tors. The period from primary surgery to metastasis appeared to
be somewhat longer in the CVD group (7.7 2.2 yr) than in the
control group (2.52  3.0 yr), but this difference was not sta-
tistically significant (P  0.107).
Effect of CVD chemotherapy on survival
Chemotherapy with the CVD regimen was initiated at times
ranging from 13 to 1271 d after the diagnosis of metastasis and
was repeated one to 21 times (mean  SD, 8.9  6.5). Nineteen
patients were treated with CVD. In 13 patients, urinary meta-
nephrines decreased to 52.4  27.5% of basal level (ranging
between 6.4 and 86%), suggesting the successful antineoplastic
effect of CVD chemotherapy. Among these patients, urinary
metanephrines returned to basal levels after 12.9 12.0months
(ranging from 2 to 36 months) in 10 patients. Three other pa-
tients still had decreased levels on the last follow-up day, i.e.
TABLE 1. Profiles of patients and disease
Profiles Control (n  9) CVD (n  16) P valuea
Female gender 5 (55.6) 5 (31.3) 0.234
Patients with paragangliomas 6 (66.7) 9 (56.3) 0.610
Other treatments
Surgeryb 2 (22.2) 7 (43.8) 0.282
MIBG 1 (11.1) 2 (12.5) 0.918
TAE 0 3 (18.8) 0.166
Deceased 3 (33.3) 10 (62.5) 0.161
At the time of pheochromocytoma diagnosis
Age (yr) 44.8  16.9 42.8  14.9 0.758
Patients with metastasis 4 (44.4) 5 (31.3) 0.509
Pulmonary metastasis 0 0
Bone metastasis 2 (22.2) 2 (12.5) 0.524
Liver metastasis 1 (11.1) 0 0.174
Local metastasis 1 (11.1) 2 (12.5) 0.918
At the time of metastasis diagnosis
Age (yr) 46.9  17.8 50.4  12.1 0.572
Years after surgery 2.2  3.0 7.7  2.2 0.107
Patients with metastasis 9 (100) 16 (100)
Pulmonary metastasis 2 (22.2) 1 (6.3) 0.238
Bone metastasis 3 (33.3) 9 (56.3) 0.271
Liver metastasis 3 (33.3) 3 (18.8) 0.412
Local metastasis 4 (44.4) 5 (31.3) 0.509
Data represent number (%), unless otherwise described.
a An unpaired t test (two-tailed) or Fischer’s exact test was used.
b Surgery was for debulking the metastasis or local invasion, not for the primary tumor.
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periods to the last follow-up day were 8, 24, and 31 months. In
six patients, urinary metanephrines never decreased to less than
90% of the basal level, and in some of these patients they even
increased. Complete remission has never been observed in any
patient with malignant pheochromocytoma.
Survival curveswere compared between the control andCVD
groups both after the time of pheochromocytoma diagnosis and
after the time of metastasis diagnosis. From time zero for the
diagnosis of pheochromocytoma, the curves were nearly identi-
cal for the control and CVD groups (2 0.2029; P 0.6524)
(Fig. 3A). From time zero for the diagnosis of metastasis, how-
ever, the control group appeared to have a slightly better survival
rate than the CVD group, although statistically, this difference
was not significant (2  2.7989; P  0.0943) (Fig. 3B).
The effects of CVDwere then analyzed after stratification for
gender, tumor type, and time of metastasis in the nine controls
and 16 patients treated with CVD. In terms of gender, women
without CVD treatment had a significantly better survival rate
than those who received CVD treatment (2  8.6406; P 
0.0345) (Fig. 4A). In men, CVD chemotherapy had no effect on
survival. In terms of tumor type, patients with adrenal pheo-
chromocytomawho received CVD treatment had a significantly
worse survival rate than all other groups (2  11.5049; P 
0.0093) (Fig. 4B). In patients with paragangliomas, CVD che-
motherapy had no effect on survival. In terms of time of metas-
tasis, patients with early metastases had better survival rates
independent of CVD therapy than those with late metastases
(2  10.7436; P  0.0013) (Fig. 4C). The survival curves of
patients with early and latemetastases are shown in Fig. 2C. The
difference between Fig. 2C and Fig. 4C reflects the difference in
whether patients whose primary tumors had not been excised
surgically were included (Fig. 2C) or not (Fig. 4C).
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FIG. 1. Survival curve for all 32 patients. A, Time zero set at the time of
pheochromocytoma diagnosis. B, Time zero set at the time of metastasis
diagnosis. Open dots represent censored observations.
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FIG. 2. Effects of patient and disease characteristics on the survival curve for
all 32 patients. A, Effect of gender. Men (thick line) and women (thin line)
had nearly identical survival curves (2  0.0061; P  0.9377 with log-rank
test). B, Effect of tumor type. Patients with extraadrenal paraganglioma (thin
line) appeared to have slightly longer survival than those with adrenal
pheochromocytoma (thick line), although statistically this difference was not
significant (2  1.4122; P  0.2347). C, Effect of time of metastasis. Patients
who already showed metastasis at the time of pheochromocytoma diagnosis
(Early meta., thick line) appeared to have slightly longer survival than those who
did not (Late meta., thin line), although statistically this difference was not
significant (2  1.5894; P  0.2074). Open dots represent censored
observations.
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Discussion
Theprognosis of a disease is evaluated in severalways.Mortality
or the survival period of remaining life is an essential marker in
a potentially lethal disease. In a malignant neoplasm with a low
incidence and with an expectation of a long remaining life, in-
formation is ordinarily accumulated by an inception cohort
study, anda survival curve is estimatedbyKaplan-Meier survival
analysis. However, to the best of our knowledge, such analysis
has never been reported in patients with malignant pheochro-
mocytoma. A few descriptive studies about mortality have been
published. John et al. (10) studied 10 patients and reported that
their survival rate was 20%at 5 yr and 0%at 10 yr. Huang et al.
(2) studied 10 patients and reported that twoof themdiedwithin
2 yr after diagnosis, but others reportedly had long survival pe-
riods. Cases with long survival were also reported by others (11,
12). Kimura et al. (13) studied 30 patients and reported that 5-
and 10-yr survival rates were 60.6 and 42.4%, respectively.
However, this study did not describe whether survival time was
counted from the time of pheochromocytoma diagnosis or from
time of metastasis diagnosis. The present study with 32 patients
demonstrated that the 50% survival period was 14.7 yr and that
the 10-yr survival rate was 61.3% from the time of pheochro-
mocytoma diagnosis. We have thus confirmed that the survival
period is variable but long, on average. Furthermore, the survival
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FIG. 4. Effects of patient and disease characteristics and CVD therapy on survival
curves. Nine controls and 16 patients who received CVD therapy were compared
after seven patients were excluded from the study by the exclusion criteria (see
text). A, Effect of gender. Women without CVD (Women w/o CVD, thin solid
line; n  5) showed longer survival than men without CVD (Men w/o CVD, thick
solid line; n  4), men receiving CVD (Men w/ CVD, broken line; n  11), or
women receiving CVD (Women w/ CVD, dotted line; n  5) (2  8.6406; P 
0.0345). B, Effect of tumor type. Patients with adrenal pheochromocytoma
receiving CVD (Adrenal w/ CVD, dotted line; n  7) had shorter survival than
those with extraadrenal paraganglioma without CVD (Extraadrenal w/o CVD, thin
solid line; n  6), those with adrenal pheochromocytoma without CVD (Adrenal
w/o CVD, thick solid line; n  3), and those with extraadrenal paraganglioma
receiving CVD (Extraadrenal w/ CVD, broken line; n  9) (2  11.5049; P 
0.0093). C, Effect of time of metastasis. Patients who already showed metastasis
at the time of pheochromocytoma diagnosis and who were treated with CVD
(Early meta. w/ CVD, thick solid line; n  5) or not (Early meta. w/o CVD, dotted
line; n  3) had longer survival than those who did not initially have metastases
and who were treated with CVD (Late meta. w/ CVD, broken line; n  13) or not
(Late meta. w/o CVD, thin solid line; n  4) (2  10.7436; P  0.00132). Open
dots represent censored observations.
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FIG. 3. Survival curves of control and CVD-treated patients. Nine controls (thick
lime) and 16 patients (thin line) who received CVD therapy were compared after
seven patients were excluded from the study by the exclusion criteria (see text).
A, Time zero set at the time of pheochromocytoma diagnosis. B, Time zero set at
the time of metastasis diagnosis. Open dots represent censored observations.
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curve in our study showed a continuous and linear decline from
the time of diagnosis for at least 20 yr. When the curve was
analyzed from the time of metastasis diagnosis, it was linear for
the first 10yr and thenbecame flat.This finding supports the idea
that some (6 of 32; 18.8%) malignant pheochromocytoma pa-
tients have an extremely long survival time. The only significant
difference we found between patients with short survival and
those with long survival was average age. Patients with long
survival were younger than the others.
We also analyzed the effects of gender, tumor type, and time
of metastasis. No significant effects were observed for any of
these factors (Fig. 2, A–C). However, patients with early metas-
tasis had aworse survival rate during the initial 5 yr but then had
better survival than those with late metastasis. From the stand-
point of clinical practice, an estimation of survival time is im-
portant when a patient is diagnosed with a lethal disease. There-
fore, a major goal of our study was to estimate the survival rate
and curve of malignant pheochromocytoma patients from the
time of metastasis, particularly in those patients whose primary
tumors could be surgically excised.
We found that CVD chemotherapy decreased urinary meta-
nephrine excretion inmost patients. However, this effect did not
continue for longperiods of time as Scholz et al. (5) reported.The
overall survival rate after the timeofmetastasis diagnosiswasnot
statistically different between theCVDand control groups; how-
ever, it did approach statistical significance (P  0.0943). We
analyzed the effects of CVD after the stratification of patients by
gender, tumor type, and time of metastasis onset. Women with-
outCVDhadbetter survival thanwomenwithCVDormenwith
or without CVD (Fig. 4A). Two of the women in our study
received chemotherapy only once or twice and then stopped due
to the adverse effects of chemotherapy toxicity. They were in-
cluded in the CVD group based on the principle of intention-to-
treat. This suggested that there is a greater toxicity of chemo-
therapy in women than in men. There have been no previous
reports suggesting that gender differencesmay affect the survival
time of patients with malignant pheochromocytoma. However,
in another malignant tumor, advanced non-small cell lung can-
cer, survival time is significantly longer in women than in men,
and chemotherapy toxicity is generally greater in women than in
men (14). The present study raises the possibility that female
gender is a negative prognostic factor for CVD chemotherapy.
Next, we analyzed the effects of tumor type and found that pa-
tients who had adrenal pheochromocytoma and underwent
CVD therapy had worse survival than other groups (Fig. 4B).
Therefore, adrenal pheochromocytomamay be a negative prog-
nostic factor for CVD chemotherapy. Finally, we analyzed the
effects of time ofmetastasis onset. Patients with earlymetastases
had better survival than those with late metastases independent
of the absence or presence of CVD chemotherapy (Fig. 4C). As
shown in Fig. 2C, patients with early metastases had worse sur-
vival during the first 5 yr and then showed better survival than
those with late metastasis. This initial poor survival was due to
patients with a poor prognosis who had not undergone surgical
excision of their primary tumors. After excluding these patients,
the survival rateswere statistically significantly better in patients
with early metastases than those with late metastases (Fig. 4C).
This observationwas unexpected and cannot be explained based
on the present study. However, this is an important finding sug-
gesting that initial diagnosiswithmetastaticpheochromocytoma
does not indicate a worse prognosis. We also observed that the
period fromthe timeofpheochromocytomadiagnosis to the time
of metastasis diagnosis tended to be shorter in the CVD group
than in the control group.Others have reported that a long tumor-
free period after surgical excision of the primary tumor was not
associatedwith a greater overall longevity than that seen inpatients
whose residual malignancy was observed sooner (1, 13). Taken
together, these findings suggest thatpheochromocytomaofadrenal
origin and female gender are negative prognostic factors for CVD
chemotherapy and that the patients’ prognosis is not worsened by
the finding of metastasis at the time of pheochromocytoma diag-
nosis if their primary tumors are surgically excised.
This study was a retrospective and nonrandomized control
study. It should be noted that somebiases and confounders could
not be avoided in our study design. For example, patients with-
out metastasis can be cured by surgical excision of the primary
tumor alone and were not diagnosed with malignant pheochro-
mocytoma.Therefore, theywerenot enrolled in this study. Inour
comparison between the control andCVDgroups, several biases
could not be excluded. Although we did not observe any differ-
ences in patient or disease profiles between these two groups, it
is possible that theCVDgroupmay have contained patientswith
more aggressive and imminently threatening disease, whereas
the control groupmayhave containedmorepatientswitha stable
condition (selection bias). The CVD group had a longer period
from the diagnosis of pheochromocytoma to diagnosis of me-
tastasis than the controls. If this time difference reflects lead time
bias, the CVD group might have had more advanced metastatic
tumors at the timeofmetastasis diagnosing.Additionalunknown
factors may also have affected our results. The present study is the
first report using survival analysis to determine the efficacy ofCVD
chemotherapy on malignant pheochromocytoma, but our study
may have limitations based on the study design.More cohort stud-
ies are needed to confirm the efficacy of CVD chemotherapy. Since
our studywasbasedonan inceptioncohort,data fromnewpatients
in future studies could be added to our data.
In conclusion, we have shown that the survival rate of
patients with malignant pheochromocytoma declined contin-
uously and linearly. Some patients had extremely long sur-
vival times. Although some patients already showed metas-
tases at the time of disease diagnosis, we found that these
patients had even longer survival than those with late metas-
tases after surgical excision of the primary tumor. CVD che-
motherapy using the standard regimen did not appear to be
effective for extending patients’ survival. We also found that
female gender and adrenal pheochromocytomas may be neg-
ative prognostic factors for CVD chemotherapy.
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